Dr. Catherine Stehman-Breen, M.D., M.S., has been the Chief Medical Officer and Senior Vice President of Sarepta Therapeutics, Inc. since April 3, 2017 and Seres Therapeutics, Inc. since April 2017. Dr. Stehman-Breen joined Sarepta after having served as Vice President of Clinical Development and Regulatory Affairs at Regeneron Pharmaceuticals since 2015 until March 2017, initially as Head of Pain Therapeutic Area and subsequently as Head of Clinical Project Management and Operations. From 2003 to 2015, she held senior leadership roles at Amgen including Vice President of Global Development, leading the neuroscience, nephrology and bone therapeutic areas. Dr. Stehman-Breen spent six years as a faculty member in the Division of Nephrology at the University of Washington from 1997 to 2003, where her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in kidney disease patients. Dr. Stehman-Breen was also active in a variety of national programs including serving as the Chair for USRDS NIDDK External Expert Panel and a reviewer for several journals. Dr. Stehman-Breen earned her M.D. from the University of Chicago in 1990. She holds a Bachelor of Arts (B.A.) from Colby College and Master of Science (M.S.) in Epidemiology from the University of Washington in 1996.